(PharmaNewsWire.Com, July 11, 2017 ) Influenza, also known as flu, is a contagious disease which spreads from person to person very rapidly. When an infected person sneezes or coughs the virus spreads to those close by, affecting immuno-compromised patients the most. The influenza virus is broadly classified as influenza A, influenza B, and influenza C. The influenza vaccine come in both inactive and weakened viral forms.
The global influenza vaccine market is relatively untouched and has huge potential to treat any major outbreak. The influenza vaccine market in the US is the largest market globally because of its strong dynamics and a great scope of innovation in the region. The growth factors of the market include increase in incidence of H1N1 outbreaks, rising spending on public healthcare programs, growth of the market in emerging economies, escalating ageing population and increase in spending on medicines and healthcare expenditure.
The global influenza vaccine market is trending with development of new drugs, use of new technologies, rise in FDA approvals, and increase in efficiency rate of influenza vaccines, booming public private partnership and growing awareness. However, the market growth will be hindered by complex development and production process, unclear process for introduction of new vaccines and high R&D costs.
The report offers an in-depth analysis of the global influenza vaccine market along with regional insights. The top notch players in the market exhibit a very close competition. The report profiles Sanofi S.A, Novartis AG, AstraZeneca PLC and GlaxoSmithKline Plc.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
